Competitive androgen receptor antagonists are used to treat prostate cancer but, even in the presence of such drugs, overexpression of androgen receptors can drive cellular proliferation ...

The key to this resistance may lie in expression of the androgen receptor itself. Most patients with metastatic prostate cancer receive drugs that block production of androgen, which promotes ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical ...

Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their ...

CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have ...

Evan Y. Yu, MD, discusses how safety data for first-line androgen deprivation therapy plus androgen receptor pathway inhibitors (ARPI) regimens such as darolutamide, abiraterone, enzalutamide, and ...

Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in ...

On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...